TP53 gene
chronic lymphocytic leukemia
clinical biomarkers
hematological parameters
polymorphism 72
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
08
2023
accepted:
30
09
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Genetic variations in A case-control study was conducted in Tunisia from February 2019 to November 2021, 160 Pro variant was associated with higher susceptibility to CLL than Arg variant (p= 0.023). A significant association was found between Pro variant and prognostic classification of Binet stage C (p= 0.001), low hemoglobin level (p= 0.003) and low platelet count (p= 0.016). We suggest that Pro variant may increase the risk of developing CLL in our population and could be associated with the severity of the disease.
Sections du résumé
Background
UNASSIGNED
Genetic variations in
Materials and methods
UNASSIGNED
A case-control study was conducted in Tunisia from February 2019 to November 2021, 160
Results
UNASSIGNED
Pro variant was associated with higher susceptibility to CLL than Arg variant (p= 0.023). A significant association was found between Pro variant and prognostic classification of Binet stage C (p= 0.001), low hemoglobin level (p= 0.003) and low platelet count (p= 0.016).
Conclusion
UNASSIGNED
We suggest that Pro variant may increase the risk of developing CLL in our population and could be associated with the severity of the disease.
Identifiants
pubmed: 37909012
doi: 10.3389/fonc.2023.1272876
pmc: PMC10613635
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1272876Informations de copyright
Copyright © 2023 Ounalli, Moumni, Mechaal, Chakroun, Barmat, Rhim, Menif and Safra.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hematol Transfus Cell Ther. 2020 Jul - Sep;42(3):261-268
pubmed: 32660851
Asian Pac J Cancer Prev. 2019 May 25;20(5):1579-1585
pubmed: 31128065
Front Oncol. 2020 Nov 06;10:595187
pubmed: 33240819
J Cancer. 2019 Jun 9;10(15):3444-3449
pubmed: 31293648
Int J Hematol Oncol Stem Cell Res. 2021 Jul 1;15(3):160-169
pubmed: 35082997
Ann Oncol. 2017 Feb 1;28(2):218-227
pubmed: 27803007
PLoS One. 2015 Mar 16;10(3):e0118112
pubmed: 25774791
Asian Pac J Cancer Prev. 2014;15(16):6871-9
pubmed: 25169539
Tumour Biol. 2014 May;35(5):3997-4005
pubmed: 24488627
Cold Spring Harb Perspect Med. 2017 Jan 3;7(1):
pubmed: 27864306
Cell Rep. 2019 Jul 30;28(5):1370-1384.e5
pubmed: 31365877
BMC Cancer. 2005 Aug 18;5:105
pubmed: 16109171
Cancer Genet Cytogenet. 2007 Nov;179(1):36-44
pubmed: 17981213
Leuk Res. 2006 Sep;30(9):1113-8
pubmed: 16458962
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
PLoS One. 2014 Apr 18;9(4):e94874
pubmed: 24747975
Am J Hematol. 2021 Dec 1;96(12):1679-1705
pubmed: 34625994
J Mol Med (Berl). 2021 May;99(5):675-683
pubmed: 33495869
Nat Rev Dis Primers. 2017 Jan 19;3:16096
pubmed: 28102226
Cancer Manag Res. 2020 Nov 10;12:11515-11522
pubmed: 33204162
Biosci Rep. 2019 Mar 19;39(3):
pubmed: 30833364
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
J Blood Med. 2019 Nov 25;10:399-404
pubmed: 31819692
Mol Biol Rep. 2022 Sep;49(9):8291-8300
pubmed: 35705773
Rep Biochem Mol Biol. 2020 Apr;9(1):26-32
pubmed: 32821748
Leukemia. 2017 Mar;31(3):705-711
pubmed: 27680515
Front Oncol. 2021 Feb 08;10:610820
pubmed: 33628731
JCO Glob Oncol. 2021 Jan;7:56-62
pubmed: 33434067
Am J Clin Pathol. 1997 Oct;108(4):378-82
pubmed: 9322589
Front Oncol. 2022 Feb 21;12:837531
pubmed: 35265527
Cancer Med. 2020 Feb;9(3):999-1007
pubmed: 31849198
Nat Rev Cancer. 2010 Jan;10(1):37-50
pubmed: 19956173
Haematologica. 2018 Dec;103(12):1956-1968
pubmed: 30442727
Cancer Cell Int. 2021 Dec 24;21(1):703
pubmed: 34952583
JAMA Oncol. 2020 Feb 1;6(2):248-254
pubmed: 31855259
Ann Hematol. 2018 Feb;97(2):209-227
pubmed: 29032510
J Clin Pathol. 1998 May;51(5):364-9
pubmed: 9708202
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12073-12079
pubmed: 33336725
Cancer Biomark. 2015;15(4):459-65
pubmed: 25835179
Expert Opin Ther Targets. 2020 Dec;24(12):1239-1250
pubmed: 33016796
Signal Transduct Target Ther. 2023 Mar 1;8(1):92
pubmed: 36859359
Asian Pac J Cancer Prev. 2023 Feb 01;24(2):613-621
pubmed: 36853312
Biomed Res Int. 2022 Aug 13;2022:2712808
pubmed: 35996546
Onco Targets Ther. 2022 Apr 21;15:423-436
pubmed: 35479302
Am J Hematol. 2019 Nov;94(11):1266-1287
pubmed: 31364186
Exp Oncol. 2014 Dec;36(4):258-61
pubmed: 25537220
Med Oncol. 2014 Apr;31(4):908
pubmed: 24615009